Search

Your search keyword '"Rajagopalan, Prabhu"' showing total 129 results
Start Over Author "Rajagopalan, Prabhu"
129 results on '"Rajagopalan, Prabhu"'

2. A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Author

Davids, Matthew S., Brander, Danielle M., Alvarado-Valero, Yesid, Diefenbach, Catherine S., Egan, Daniel N., Dinner, Shira N., Javidi-Sharifi, Nathalie, Al Malki, Monzr M., Begna, Kebede H., Bhatt, Vijaya Raj, Abedin, Sameem, Cook, Rachel J., Collins, Mary C., Roleder, Carly, Dominguez, Edward C., Rajagopalan, Prabhu, Wiley, Sandra E., Ghalie, Richard G., and Danilov, Alexey V.

Published
2025
Full Text
View/download PDF

3. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

Author

Schuler, Martin, Cho, Byoung Chul, Sayehli, Cyrus Michael, Navarro, Alejandro, Soo, Ross A, Richly, Heike, Cassier, Philippe Alexandre, Tai, David, Penel, Nicolas, Nogova, Lucia, Park, Se Hoon, Schostak, Martin, Gajate, Pablo, Cathomas, Richard, Rajagopalan, Prabhu, Grevel, Joachim, Bender, Sebastian, Boix, Oliver, Nogai, Hendrik, Ocker, Matthias, Ellinghaus, Peter, and Joerger, Markus

Published
2019
Full Text
View/download PDF

4. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas

Author

Soumerai, Jacob D., primary, Diefenbach, Catherine S., additional, Jagadeesh, Deepa, additional, Asch, Adam, additional, Kumar, Abhijeet, additional, Tsai, Michaela L., additional, Jandl, Thomas A., additional, Lossos, Izidore S., additional, Kenkre, Vaishalee P., additional, Awan, Farrukh, additional, Novotny, William, additional, Huang, Jane, additional, Miao, Lu, additional, Rajagopalan, Prabhu, additional, Ghalie, Richard G., additional, and Zelenetz, Andrew D., additional

Published
2024
Full Text
View/download PDF

6. Supplementary Data from A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Author

Atrafi, Florence, primary, Boix, Oliver, primary, Subbiah, Vivek, primary, Diamond, Jennifer R., primary, Chawla, Sant P., primary, Tolcher, Anthony W., primary, LoRusso, Patricia M., primary, Eder, Joseph P., primary, Gutierrez, Martin, primary, Sankhala, Kumar, primary, Rajagopalan, Prabhu, primary, Genvresse, Isabelle, primary, Langer, Simon, primary, Mathijssen, Ron H.J., primary, Verweij, Jaap, primary, Bruns, Ingmar, primary, and Lolkema, Martijn P., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Table from A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Author

Atrafi, Florence, primary, Boix, Oliver, primary, Subbiah, Vivek, primary, Diamond, Jennifer R., primary, Chawla, Sant P., primary, Tolcher, Anthony W., primary, LoRusso, Patricia M., primary, Eder, Joseph P., primary, Gutierrez, Martin, primary, Sankhala, Kumar, primary, Rajagopalan, Prabhu, primary, Genvresse, Isabelle, primary, Langer, Simon, primary, Mathijssen, Ron H.J., primary, Verweij, Jaap, primary, Bruns, Ingmar, primary, and Lolkema, Martijn P., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure from A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Author

Atrafi, Florence, primary, Boix, Oliver, primary, Subbiah, Vivek, primary, Diamond, Jennifer R., primary, Chawla, Sant P., primary, Tolcher, Anthony W., primary, LoRusso, Patricia M., primary, Eder, Joseph P., primary, Gutierrez, Martin, primary, Sankhala, Kumar, primary, Rajagopalan, Prabhu, primary, Genvresse, Isabelle, primary, Langer, Simon, primary, Mathijssen, Ron H.J., primary, Verweij, Jaap, primary, Bruns, Ingmar, primary, and Lolkema, Martijn P., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Tables 1-3 from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure S1 from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure Legend from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 4 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

Author

Adjei, Alex A., primary, Richards, Donald A., primary, El-Khoueiry, Anthony, primary, Braiteh, Fadi, primary, Becerra, Carlos H.R., primary, Stephenson, Joe J., primary, Hezel, Aram F., primary, Sherman, Morris, primary, Garbo, Lawrence, primary, Leffingwell, Diane P., primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Gunawan, Sonny, primary, Wilson, David M., primary, Manhard, Kimberly J., primary, Rajagopalan, Prabhu, primary, Krissel, Heiko, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

13. Data from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 2 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

Author

Adjei, Alex A., primary, Richards, Donald A., primary, El-Khoueiry, Anthony, primary, Braiteh, Fadi, primary, Becerra, Carlos H.R., primary, Stephenson, Joe J., primary, Hezel, Aram F., primary, Sherman, Morris, primary, Garbo, Lawrence, primary, Leffingwell, Diane P., primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Gunawan, Sonny, primary, Wilson, David M., primary, Manhard, Kimberly J., primary, Rajagopalan, Prabhu, primary, Krissel, Heiko, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 1 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

Author

Adjei, Alex A., primary, Richards, Donald A., primary, El-Khoueiry, Anthony, primary, Braiteh, Fadi, primary, Becerra, Carlos H.R., primary, Stephenson, Joe J., primary, Hezel, Aram F., primary, Sherman, Morris, primary, Garbo, Lawrence, primary, Leffingwell, Diane P., primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Gunawan, Sonny, primary, Wilson, David M., primary, Manhard, Kimberly J., primary, Rajagopalan, Prabhu, primary, Krissel, Heiko, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 5 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

Author

Adjei, Alex A., primary, Richards, Donald A., primary, El-Khoueiry, Anthony, primary, Braiteh, Fadi, primary, Becerra, Carlos H.R., primary, Stephenson, Joe J., primary, Hezel, Aram F., primary, Sherman, Morris, primary, Garbo, Lawrence, primary, Leffingwell, Diane P., primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Gunawan, Sonny, primary, Wilson, David M., primary, Manhard, Kimberly J., primary, Rajagopalan, Prabhu, primary, Krissel, Heiko, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 3 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

Author

Adjei, Alex A., primary, Richards, Donald A., primary, El-Khoueiry, Anthony, primary, Braiteh, Fadi, primary, Becerra, Carlos H.R., primary, Stephenson, Joe J., primary, Hezel, Aram F., primary, Sherman, Morris, primary, Garbo, Lawrence, primary, Leffingwell, Diane P., primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Gunawan, Sonny, primary, Wilson, David M., primary, Manhard, Kimberly J., primary, Rajagopalan, Prabhu, primary, Krissel, Heiko, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 6 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

Author

Adjei, Alex A., primary, Richards, Donald A., primary, El-Khoueiry, Anthony, primary, Braiteh, Fadi, primary, Becerra, Carlos H.R., primary, Stephenson, Joe J., primary, Hezel, Aram F., primary, Sherman, Morris, primary, Garbo, Lawrence, primary, Leffingwell, Diane P., primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Gunawan, Sonny, primary, Wilson, David M., primary, Manhard, Kimberly J., primary, Rajagopalan, Prabhu, primary, Krissel, Heiko, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 1 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

Author

Adjei, Alex A., primary, Richards, Donald A., primary, El-Khoueiry, Anthony, primary, Braiteh, Fadi, primary, Becerra, Carlos H.R., primary, Stephenson, Joe J., primary, Hezel, Aram F., primary, Sherman, Morris, primary, Garbo, Lawrence, primary, Leffingwell, Diane P., primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Gunawan, Sonny, primary, Wilson, David M., primary, Manhard, Kimberly J., primary, Rajagopalan, Prabhu, primary, Krissel, Heiko, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 2 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

Author

Adjei, Alex A., primary, Richards, Donald A., primary, El-Khoueiry, Anthony, primary, Braiteh, Fadi, primary, Becerra, Carlos H.R., primary, Stephenson, Joe J., primary, Hezel, Aram F., primary, Sherman, Morris, primary, Garbo, Lawrence, primary, Leffingwell, Diane P., primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Gunawan, Sonny, primary, Wilson, David M., primary, Manhard, Kimberly J., primary, Rajagopalan, Prabhu, primary, Krissel, Heiko, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

21. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

Author

Van Laethem, Jean-Luc, Riess, Hanno, Jassem, Jacek, Haas, Michael, Martens, Uwe M., Weekes, Colin, Peeters, Marc, Ross, Paul, Bridgewater, John, Melichar, Bohuslav, Cascinu, Stefano, Saramak, Piotr, Michl, Patrick, Van Brummelen, David, Zaniboni, Alberto, Schmiegel, Wollf, Dueland, Svein, Giurescu, Marius, Garosi, Vittorio L., Roth, Katrin, Schulz, Anke, Seidel, Henrik, Rajagopalan, Prabhu, Teufel, Michael, and Childs, Barrett H.

Published
2017
Full Text
View/download PDF

22. Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Author

Atrafi, Florence, primary, Boix, Oliver, additional, Subbiah, Vivek, additional, Diamond, Jennifer R., additional, Chawla, Sant P., additional, Tolcher, Anthony W., additional, LoRusso, Patricia M., additional, Eder, Joseph P., additional, Gutierrez, Martin, additional, Sankhala, Kumar, additional, Rajagopalan, Prabhu, additional, Genvresse, Isabelle, additional, Langer, Simon, additional, Mathijssen, Ron H.J., additional, Verweij, Jaap, additional, Bruns, Ingmar, additional, and Lolkema, Martijn P., additional

Published
2022
Full Text
View/download PDF

24. A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Author

Atrafi, Florence, primary, Boix, Oliver, additional, Subbiah, Vivek, additional, Diamond, Jennifer R., additional, Chawla, Sant P., additional, Tolcher, Anthony W., additional, LoRusso, Patricia M., additional, Eder, Joseph P., additional, Gutierrez, Martin, additional, Sankhala, Kumar, additional, Rajagopalan, Prabhu, additional, Genvresse, Isabelle, additional, Langer, Simon, additional, Mathijssen, Ron H.J., additional, Verweij, Jaap, additional, Bruns, Ingmar, additional, and Lolkema, Martijn P., additional

Published
2021
Full Text
View/download PDF

25. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

Author

Hassan, Raffit, primary, Blumenschein, George R., additional, Moore, Kathleen N., additional, Santin, Alessandro D., additional, Kindler, Hedy L., additional, Nemunaitis, John J., additional, Seward, Shelly M., additional, Thomas, Anish, additional, Kim, Stella K., additional, Rajagopalan, Prabhu, additional, Walter, Annette O., additional, Laurent, Dirk, additional, Childs, Barrett H., additional, Sarapa, Nenad, additional, Elbi, Cem, additional, and Bendell, Johanna C., additional

Published
2020
Full Text
View/download PDF

29. A randomized Bayesian phase 1 design combining an MPS-1 inhibitor with paclitaxel: A strategy to improve determination of the incremental toxicity of a novel compound over a known backbone therapy.

Author

Atrafi, Florence, primary, Boix, Oliver, additional, Rajagopalan, Prabhu, additional, Tolcher, Anthony W., additional, LoRusso, Patricia, additional, Eder, Joseph Paul, additional, Sankhala, Kamalesh Kumar, additional, Chawla, Sant P., additional, Subbiah, Vivek, additional, Diamond, Jennifer Robinson, additional, Gutierrez, Martin, additional, Mathijssen, Ron H.J., additional, Mei, Jian, additional, Verweij, Jaap, additional, Bruns, Ingmar, additional, and Lolkema, Martijn P., additional

Published
2018
Full Text
View/download PDF

30. Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.

Author

Bulat, Iurie, primary, Moore, Kathleen N., additional, Haceatrean, Alexei, additional, Chung, John Woojune, additional, Rajagopalan, Prabhu, additional, Xia, Chenghua, additional, Laurent, Dirk, additional, Childs, Barrett H., additional, and Santin, Alessandro, additional

Published
2018
Full Text
View/download PDF

31. Abstract A095: Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer

Author

Hassan, Raffit, primary, Wang, Ding, additional, Wrangle, John, additional, Thomas, Anish, additional, Byars, Angus, additional, Asschert, Lianne, additional, Atienza, Rolando, additional, Rajagopalan, Prabhu, additional, Walter, Annette, additional, Zhang, Jun, additional, Sarapa, Nenad, additional, and Kindler, Hedy, additional

Published
2018
Full Text
View/download PDF

32. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

Author

Bahleda, Rastislav, primary, Grilley-Olson, Juneko E, additional, Govindan, Ramaswamy, additional, Barlesi, Fabrice, additional, Greillier, Laurent, additional, Perol, Maurice, additional, Ray-Coquard, Isabelle, additional, Strumberg, Dirk, additional, Schultheis, Beate, additional, Dy, Grace K, additional, Zalcman, Gérard, additional, Weiss, Glen J, additional, Walter, Annette O, additional, Kornacker, Martin, additional, Rajagopalan, Prabhu, additional, Henderson, David, additional, Nogai, Hendrik, additional, Ocker, Matthias, additional, and Soria, Jean-Charles, additional

Published
2017
Full Text
View/download PDF

33. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

Author

Van Laethem, Jean-Luc, primary, Riess, Hanno, additional, Jassem, Jacek, additional, Haas, Michael, additional, Martens, Uwe M., additional, Weekes, Colin, additional, Peeters, Marc, additional, Ross, Paul, additional, Bridgewater, John, additional, Melichar, Bohuslav, additional, Cascinu, Stefano, additional, Saramak, Piotr, additional, Michl, Patrick, additional, Van Brummelen, David, additional, Zaniboni, Alberto, additional, Schmiegel, Wollf, additional, Dueland, Svein, additional, Giurescu, Marius, additional, Garosi, Vittorio L., additional, Roth, Katrin, additional, Schulz, Anke, additional, Seidel, Henrik, additional, Rajagopalan, Prabhu, additional, Teufel, Michael, additional, and Childs, Barrett H., additional

Published
2016
Full Text
View/download PDF

35. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

Author

Adjei, Alex A., primary, Richards, Donald A., additional, El-Khoueiry, Anthony, additional, Braiteh, Fadi, additional, Becerra, Carlos H.R., additional, Stephenson, Joe J., additional, Hezel, Aram F., additional, Sherman, Morris, additional, Garbo, Lawrence, additional, Leffingwell, Diane P., additional, Iverson, Cory, additional, Miner, Jeffrey N., additional, Shen, Zancong, additional, Yeh, Li-Tain, additional, Gunawan, Sonny, additional, Wilson, David M., additional, Manhard, Kimberly J., additional, Rajagopalan, Prabhu, additional, Krissel, Heiko, additional, and Clendeninn, Neil J., additional

Published
2016
Full Text
View/download PDF

36. A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma

Author

Lim, Ho Yeong, primary, Heo, Jeong, additional, Choi, Hye Jin, additional, Lin, Cheng-Yao, additional, Yoon, Jung-Hwan, additional, Hsu, Chiun, additional, Rau, Kun-Ming, additional, Poon, Ronnie T.P., additional, Yeo, Winnie, additional, Park, Joong-Won, additional, Tay, Miah Hiang, additional, Hsieh, Wen-Son, additional, Kappeler, Christian, additional, Rajagopalan, Prabhu, additional, Krissel, Heiko, additional, Jeffers, Michael, additional, Yen, Chia-Jui, additional, and Tak, Won Young, additional

Published
2014
Full Text
View/download PDF

37. A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer.

Author

Ramanathan, Ramesh K., primary, Von Hoff, Daniel D., additional, Eskens, Ferry, additional, Blumenschein, George R., additional, Richards, Donald A., additional, Renshaw, Frank Gary, additional, Rajagopalan, Prabhu, additional, Kelly, Andrea, additional, Pena, Carol Elaine, additional, and Mross, Klaus B., additional

Published
2014
Full Text
View/download PDF

38. Abstract LB-291: First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.

Author

Bendell, Johanna, primary, Blumenschein, George, additional, Zinner, Ralph, additional, Hong, David, additional, Jones, Suzanne, additional, Infante, Jeffrey, additional, Burris, Howard, additional, Rajagopalan, Prabhu, additional, Kornacker, Martin, additional, Henderson, David, additional, Kelly, Andrea, additional, and Hassan, Raffit, additional

Published
2013
Full Text
View/download PDF

39. Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., additional, Adjei, Alex A., additional, Leffingwell, Diane P., additional, Eckhardt, S. Gail, additional, Gore, Lia, additional, Lewis, Karl D., additional, Weiss, Glen J., additional, Ramanathan, Ramesh K., additional, Dy, Grace K., additional, Ma, Wen W., additional, Sheedy, Beth, additional, Iverson, Cory, additional, Miner, Jeffrey N., additional, Shen, Zancong, additional, Yeh, Li-Tain, additional, Dubowy, Ronald L., additional, Jeffers, Michael, additional, Rajagopalan, Prabhu, additional, and Clendeninn, Neil J., additional

Published
2013
Full Text
View/download PDF

40. Phase I Study of Intravenous PI3K Inhibitor Bay 80–6946: Preliminary Activity in Patients with Relapsed Non-Hodgkin Lymphoma (NHL) Treated in an MTD Expansion Cohort

Author

Patnaik, Amita, primary, Ramanathan, Ramesh K, additional, Appleman, Leonard Joseph, additional, Tolcher, Anthony W, additional, Mountz, James M, additional, Beerham, Muralidhar, additional, Weiss, Glen J, additional, Rasco, Drew W, additional, Lotze, Michael T, additional, Toledo, Frederico GS, additional, Oborski, Matthew J, additional, Rajagopalan, Prabhu, additional, Jeffers, Michael, additional, Kelly, Andrea, additional, and Genvresse, Isabelle, additional

Published
2012
Full Text
View/download PDF

41. Phase I study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts.

Author

Lotze, Michael T., primary, Appleman, Leonard Joseph, additional, Ramanathan, Ramesh K., additional, Tolcher, Anthony W., additional, Beeram, Muralidhar, additional, Papadopoulos, Kyriakos P., additional, Rasco, Drew Warren, additional, Weiss, Glen J., additional, Mountz, James M, additional, Toledo, Frederico G.S., additional, Alvarez, Rene J, additional, Oborski, Matthew J, additional, Rajagopalan, Prabhu, additional, Jeffers, Michael, additional, Roth, Diane, additional, Dubowy, Ronald L., additional, and Patnaik, Amita, additional

Published
2012
Full Text
View/download PDF

43. A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.

Author

Van Laethem, Jean-Luc, primary, Heinemann, Volker, additional, Martens, Uwe Marc, additional, Jassem, Jacek, additional, Michl, Patrick, additional, Peeters, Marc, additional, Weekes, Colin D., additional, Maréchal, Raphael, additional, Stieler, Jens, additional, Giurescu, Marius, additional, Rajagopalan, Prabhu, additional, Garosi, Vittorio Luigi, additional, and Riess, Hanno, additional

Published
2012
Full Text
View/download PDF

44. A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC).

Author

Lim, Ho Yeong, primary, Yen, Chia-Jui, additional, Tak, Won-Young, additional, Heo, Jeong, additional, Choi, Hye Jin, additional, Lin, Cheng-Yao, additional, Yoon, Jung-Hwan, additional, Hsu, Chiun, additional, Rau, Kun-Ming, additional, Poon, Ronnie Tung Ping, additional, Yeo, Winnie, additional, Park, Joong-Won, additional, Tay, Miah Hiang, additional, Hsieh, Wen Son, additional, Kappeler, Christian, additional, Rajagopalan, Prabhu, additional, and Krissel, Heiko, additional

Published
2012
Full Text
View/download PDF

46. Abstract A88: Safety, pharmacokinetic, and pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients.

Author

Adjei, Alex A., primary, Richards, Donald A., additional, El-Khoueiry, Anthony, additional, Becerra, Carlos H.R., additional, Stephenson, Joe J., additional, Leffingwell, Diane P., additional, Iverson, Cory, additional, Miner, Jeffrey N., additional, Shen, Zancong, additional, Gunawan, Sonny, additional, Wilson, David, additional, Manhard, Kimberly J., additional, Dubowy, Ron L., additional, Jeffers, Michael, additional, Rajagopalan, Prabhu, additional, Franklin, Wilbur A., additional, Haney, Jerry, additional, Lenhart, Patricia, additional, and Clendeninn, Neil J., additional

Published
2011
Full Text
View/download PDF

47. Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer

Author

Mross, Klaus, primary, Frost, Annette, additional, Scheulen, Max E, additional, Krauss, Jürgen, additional, Strumberg, Dirk, additional, Schultheiss, Beate, additional, Fasol, Ulrike, additional, Büchert, Martin, additional, Krätzschmer, Jörn, additional, Delesen, Heinz, additional, Rajagopalan, Prabhu, additional, and Christensen, Olaf, additional

Published
2011
Full Text
View/download PDF

48. Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors

Author

Eskens, Ferry A.L.M., primary, Steeghs, Neeltje, additional, Verweij, Jaap, additional, Bloem, Johan L., additional, Christensen, Olaf, additional, van Doorn, Leni, additional, Ouwerkerk, Jan, additional, de Jonge, Maja J.A., additional, Nortier, Johan W.R., additional, Kraetzschmar, Joern, additional, Rajagopalan, Prabhu, additional, and Gelderblom, Hans, additional

Published
2009
Full Text
View/download PDF

50. Safety, Tolerability, Pharmacokinetics, and Efficacy of an Interleukin-2 Agonist Among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy

Author

Davey, Richard T., primary, Pertel, Peter E., additional, Benson, Alice, additional, Cassell, Delanie J., additional, Gazzard, Brian G., additional, Holodniy, Mark, additional, Lalezari, Jacob P., additional, Levy, Yves, additional, Mitsuyasu, Ronald T., additional, Palella, Frank J., additional, Pollard, Richard B., additional, Rajagopalan, Prabhu, additional, Saag, Michael S., additional, Salata, Robert A., additional, Sha, Beverly E., additional, and Choudhri, Shurjeel, additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results